Screening cancer patients for better access to clinical trials

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

SPECTA is a platform designed to collect various biological materials and data from cancer patients to enhance translational research and clinical studies. It focuses on gathering clinicopathological information, imaging data, and patient-reported outcomes to support biomarker discovery and improve cancer care. Patients are recruited for multiple downstream projects that utilize this comprehensive data for research purposes.

Why it matters

Who can join: the full rules

* Patients with pathologically confirmed selected tumor types (at site or centrally);
* Mandatory availability of adequate human biological material (HBM);
* Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements;
* Age ≥ 12 years;
* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
* Written informed consent according to applicable legal and ethical requirements;

Where it's running

• Medical University Vienna - General Hospital AKH
  Vienna, Austria Recruiting
• Onze Lieve Vrouw Ziekenhuis
  Aalst, Belgium Recruiting
• ZAS Middelheim
  Antwerp, Belgium Recruiting
• Hopitaux Universitaires - Institut Jules Bordet
  Brussels, Belgium Recruiting
• Universitair Ziekenhuis Brussel
  Brussels, Belgium Recruiting
• Cliniques Universitaires Saint-Luc
  Brussels, Belgium Recruiting

+86 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Eortc Hq
• Email: specta@eortc.org
• Phone: +32 2 774 1611

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Radiotherapy for BCG-Unresponsive Bladder CIS

  This study tests whether radiation therapy can help people with BCG-unresponsive non-muscle-invasive bladder cancer to delay or avoid bladder removal.

  Recruiting at 3 sites European Organisation for Research and Treatment of Cancer - EORTC · Anderlecht, Brussels Capital and 2 other locations · NCT06990061

• Vorasidenib as daily maintenance therapy for adults with IDH‑mutant grade 2–3 astrocytoma

  This trial will test whether taking daily vorasidenib after chemoradiotherapy delays tumor progression compared with placebo in adults with IDH‑mutant grade 2 or 3 astrocytoma.

  Recruiting at 35 sites Phase 3 European Organisation for Research and Treatment of Cancer - EORTC · Bedford Park and 58 other locations · NCT06809322

• Radiopharmaceutical treatment for advanced kidney cancer using 177Lu-PSMA-617

  This study tests whether 177Lu-PSMA-617 can help adults with metastatic clear cell renal cell carcinoma that has progressed after immunotherapy and a VEGFR-TKI.

  Recruiting at 2 sites Phase 2 European Organisation for Research and Treatment of Cancer - EORTC · Caen and 1 other locations · NCT06783348

• Single‑fraction versus multiple‑fraction SBRT for treating limited metastases (SPRINT)

  This trial will test whether a single high‑dose SBRT treatment works as safely and effectively as multiple smaller SBRT treatments for people with limited metastases from breast, prostate, lung, or colorectal cancer.

  Recruiting at 2 sites European Organisation for Research and Treatment of Cancer - EORTC · Aalst and 14 other locations · NCT06462963

• Using 177Lu-DOTATATE to treat recurrent meningioma

  This study is testing if a new targeted treatment called 177Lu-DOTATATE can help people with recurrent meningioma who haven't had success with regular treatments like surgery and radiation.

  Recruiting at 17 sites Phase 2 European Organisation for Research and Treatment of Cancer - EORTC · Innsbruck and 18 other locations · NCT06326190

• Using Tebentafusp to prevent recurrence in high-risk ocular melanoma patients

  This study is testing if a new treatment called tebentafusp can help prevent the return of high-risk uveal melanoma in patients after their initial treatment.

  Recruiting at 15 sites Phase 3 European Organisation for Research and Treatment of Cancer - EORTC · Lake Success, New York and 14 other locations · NCT06246149

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.